Opioid Withdrawal Management

Assessment and Treatment Initiation

Buprenorphine is the first-line treatment for acute opioid withdrawal, demonstrating superior efficacy to all alternatives in reducing withdrawal severity, increasing treatment completion rates, and improving long-term outcomes 1
The American College of Emergency Physicians recommends specific waiting periods before buprenorphine initiation, including waiting >12 hours since last use of short-acting opioids and >24 hours for extended-release formulations 2, 3
Administer buprenorphine ONLY to patients in active opioid withdrawal to avoid precipitating severe withdrawal due to its high binding affinity and partial agonist properties 2, 3

For patients with COWS >8, the initial dose of buprenorphine is 4-8 mg sublingual based on withdrawal severity, with a target first-day dose of 8-16 mg total 1, 2, 3
The American College of Emergency Physicians recommends prescribing buprenorphine/naloxone 16 mg sublingual daily for 3-7 days or until follow-up appointment for X-waivered providers 2, 3
Buprenorphine has an 85% probability of being the most effective treatment, compared to 12.1% for methadone, 2.6% for lofexidine, and 0.01% for clonidine 4

Regardless of primary agent used, add symptom-specific medications, including antiemetics for nausea, loperamide for diarrhea, and benzodiazepines for anxiety/muscle cramps 1, 2

The American College of Emergency Physicians strongly recommends providing overdose prevention education and naloxone kits, as patients become more sensitive to opioid effects after withdrawal, increasing overdose risk if they resume use 1, 2, 3
Hepatitis C and HIV screening, as well as reproductive health counseling, are also recommended 2

Medication for addiction treatment saves lives, and buprenorphine is not just for withdrawal management but for long-term treatment of opioid use disorder 2, 3
Discontinuing buprenorphine therapy can precipitate withdrawal and increase the risk of relapse to illicit opioid use 3